09:40 AM EST - Oncolytics Biotech Inc : Announced recent operational highlights and financial results for the fourth quarter and year ended December 31, 2023. Highlights include; Pelareorep advancing to a registration-enabling study in 2024 in pancreatic cancer and expands pancreatic potential with new GOBLET cohort in combination with mFOLFIRINOX; Impressive objective response rate in GOBLET study anal carcinoma cohort supports enrollment expansion;
Expecting to report overall survival data from BRACELET-1 breast cancer study in 2024; Cash position of $34.9 million provides runway through critical milestones into 2025. Oncolytics Biotech Inc
shares T.ONC are trading unchanged at $1.41.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=ONCY&qmodStoryID=8212656846144146
